Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with ...

BIOTRONIK’s BIO│WOMEN Study Enrolled 474 Patients Across Eight Countries in Europe and IsraelAddressing Critical Gaps as Women Often Remain Undiagnosed and Undertreated in Heart FailureThis ...

Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...

It's dangerous in medicine to make decisions based solely on what makes intuitive sense. At the European Society of Cardiology (ESC) Congress 2023, we learned from the BUDAPEST CRT trial that the ...

August 11, 2008 (Durham, NC) — There is a large variation in the use of cardiac resynchronization therapy (CRT) throughout the US, and this technology is not always ...

Please provide your email address to receive an email when new articles are posted on . 4D model-guided cardiac resynchronization lead placement improved left ventricular function vs. standard care.

Washington, DC - Heart failure treated with cardiac resynchronization therapy (CRT) is most likely to improve clinically and least likely to cause hospitalization or death when the biventricular ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...